Phase III Clinical Trial of Y-2 Sublingual Tablet in the Treatment of Acute Ischemic Stroke - a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Y-2 (Primary) ; Borneol
- Indications Stroke
- Focus Therapeutic Use
- 12 Dec 2022 Status changed from recruiting to completed.
- 12 Jul 2021 New trial record